A potential drug targeting Alzheimer’s and Schizophrenia, developed by Hyderabad-based Suven Life Sciences, has commenced the Phase I clinical trial in the US.
According to the company, the new chemical entity (NCE) is a potent, selective, brain penetrant and an orally active histamine for the treatment of cognitive dysfunction associated with the age-related diseases, which do not have effective curative treatments at present.
It has completed all the pre-clinical, safety and early toxicological studies. Suven has submitted data for the Investigational New Drug Application, a request for the US Food and Drug Administration authorisation to conduct the Phase 1 clinical trial of the investigational drug, a press release said on Monday.
The company has 11 therapeutic drug candidates in pre-clinical state of development, targeting dementia, major depressive disorder, Huntington’s disease, Parkinson’s and obesity, said Venkat Jasti, CEO of Suven.
Interestingly, in the past few months, a couple of global research studies have pointed to encouraging results from potential drugs to treat Alzheimer’s.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.